Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data

INTRODUCTION: Despite the benefits of direct oral anti-Xa anticoagulants (DOACs), the risk–benefit profile of DOAC therapy compared to warfarin therapy in patients with non-valvular atrial fibrillation (AF) and chronic kidney disease (CKD), including end-stage renal disease (ESRD), is uncertain. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Kee, Youn Kyung, Jeon, Hee Jung, Oh, Jieun, Yoo, Tae-Hyun, Kang, Dongwoo, Lee, Jungkuk, Shin, Dong Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541953/
https://www.ncbi.nlm.nih.gov/pubmed/37786900
http://dx.doi.org/10.3389/fmed.2023.1212816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541953/
https://www.ncbi.nlm.nih.gov/pubmed/37786900
http://dx.doi.org/10.3389/fmed.2023.1212816

Ejemplares similares